Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

CVS Caremark Corporation : U.S. asks CVS about its prescription discount plan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/17/2012 | 10:28pm CET

CVS Caremark Corp said it received requests for information about a prescription drug discount program it runs for uninsured or under-insured individuals from both the U.S. government and the Texas Attorney General.

In January, CVS received a subpoena from the U.S. Office of Inspector General requesting information about the company's Health Savings Pass program, CVS said in its 10k filing on Friday.

The company, which runs the CVS pharmacy chain and the CVS Caremark pharmacy benefits management service, said the request was connected to an investigation of possible false or otherwise improper claims for payment involving Health & Human Services programs.

In February, CVS received a civil investigative demand from Texas' Office of the Attorney General. That office requested a copy of information from the OIG subpoena and other information related to prescription drug claims submitted by CVS pharmacies to Texas Medicaid for reimbursement, the company said.

CVS said it would respond to the requests for information and cooperate with both investigations.

CVS markets its Health Savings Pass, which has a $15 annual fee, to people who do not have prescription drug coverage and to those who have limited coverage.

The Health Savings Pass lets patients fill 90-day prescriptions for 400 generic drugs for $11.99. Participants also get discounts such as 10 percent off visits at the CVS in-store health clinic, MinuteClinic and 10 percent off an annual flu shot.

The announcement comes about a month after CVS agreed to pay $5 million to settle charges of inaccurate pricing of some drugs for the elderly and disabled, ending a wide-ranging, multi-year probe into its business practices.

Shares of CVS closed down 28 cents at $44.27, after reaching a new high of $45 earlier in the day.

(Reporting by Jessica Wohl in Chicago; Editing by Richard Chang)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORP
09:55a Star Tribune (Minneapolis) Lee Schafer column
12/07 CVS HEALTH : Pharmacy and MinuteClinic Encourage Families to Get Their Flu Shots..
12/07 CVS HEALTH : New restrictions on drug coverage are threat to patients
12/06 PRESCRIPTION DRUG PRICING : The Experts Weigh In
12/06 CVS HEALTH : When Severe Weather Strikes, Be Prepared
12/05 CVS HEALTH : Hexavest Inc. Has $49,682,000 Stake in CVS Health Corporation
12/05 CVS HEALTH : and HHS Study Finds Proactive Pharmacy-based Outreach Helps Patient..
12/05 CVS HEALTH : Achieves 100 Percent on 2017 Corporate Equality Index for Third Con..
12/05 CVS HEALTH : Achieves 100 Percent on 2017 Corporate Equality Index for Third Con..
12/05 CVS HEALTH : To Host 2016 Analyst Day For The Investment Community
More news
Sector news : Drug Retailers - NEC
11/16DJWALGREENS BOOTS ALLIANCE : Claims Theranos Voided 11.3% of Test Reports
11/10 Trump victory clouds outlook for Time Warner-AT&T, other mergers
11/09 Trump stand on AT&T/Time Warner not indicative of M&A policy - analysts
11/09DJWALGREENS BOOTS ALLIANCE : Walgreen Sues Theranos, Seeking to Recover $140 Milli..
11/08DJWALGREENS BOOTS ALLIANCE : Seeks to Recover $140 Million Investment From Therano..
More sector news : Drug Retailers - NEC
News from SeekingAlpha
11:45a Cardinal Health Has My Attention
10:31a Should You Follow These Analyst Recommendations?
12/07 Is Rebalancing A Stock Portfolio A Form Of Value Investing?
12/05 10 Dividend Growth Stock For December 2016
12/05 NOVEMBER PORTFOLIO ROUNDUP : 2 Buys, 1 New Position
Advertisement
Financials ($)
Sales 2016 178 047 M
EBIT 2016 10 769 M
Net income 2016 5 740 M
Debt 2016 24 598 M
Yield 2016 2,04%
P/E ratio 2016 15,95
P/E ratio 2017 14,81
EV / Sales 2016 0,62x
EV / Sales 2017 0,59x
Capitalization 85 880 M
More Financials
Chart CVS HEALTH CORP
Duration : Period :
CVS Health Corp Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH CORP
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 86,8 $
Spread / Average Target 7,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Stephen J. Gold Chief Information Officer & Executive Vice Preside
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORP-17.63%85 880
WALGREENS BOOTS ALLIAN..-0.26%92 068
EXPRESS SCRIPTS HOLDIN..-13.23%46 771
MCKESSON CORPORATION-28.20%32 018
CARDINAL HEALTH INC-21.03%22 564
AMERISOURCEBERGEN CORP..-26.35%16 811
More Results